Drugs for Penile Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 98)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Fentanyl |
Approved, Illicit, Investigational, Vet_approved |
Phase 3 |
|
437-38-7 |
3345
|
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-phenethyl-4-N-propionylanilinopiperidine
1-Phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Actiq
BIDD:GT0555
BRN 0494484
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
fentanyl
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl [INN:BAN]
Fentanyl CII
Fentanyl citrate
Fentanyl-100
Fentanyl-12
Fentanyl-25
|
Fentanyl-50
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
HSDB 3329
IONSYS
JNS020QD
L001275
LS-124439
Matrifen
MolPort-003-847-369
N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
Nasalfent
NCGC00168252-01
N-phenethyl-4-(N-propionylanilino)piperidine
N-Phenethyl-4-(N-propionylanilino)piperidine
N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
UNII-UF599785JZ
|
|
2 |
|
Cisplatin |
Approved |
Phase 3,Phase 2,Phase 1 |
|
15663-27-1 |
2767
441203
84093
|
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
Carboquone
CDDP
CHEBI:35852
CID441203
Cis Pt II
cis-[PtCl2(NH3)2]
cis-DDP
Cis-DDP
Cis-Diaminedichloroplatinum
cis-diamminedichloridoplatinum(II)
cis-Diamminedichloroplatinum
Cis-Diamminedichloroplatinum
cis-diamminedichloroplatinum(II)
cis-Dichlorodiammineplatinum(II)
Cismaplat
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
CPD0-1392
CPDC
|
CPDD
DB00515
DDP
DDPT
Diamminedichloroplatinum
EU-0100918
Lederplatin
nchembio773-comp1
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
Trans-DDP
Trans-Diaminedichloroplatinum
trans-diamminedichloridoplatinum(II)
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
|
|
3 |
|
Ifosfamide |
Approved |
Phase 3,Phase 2 |
|
3778-73-2 |
3690
|
Synonyms:
(+-)-Ifosfamid
(+-)-Ifosphamide
(+-)-Tetrahydro-N,3-bis(2-chloroethyl)-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
(D,L)-Ifosfamide
(R,S)-Ifosphamide
(R,S)-N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
{3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,
1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide
1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide
2,3-(N,N(sup 1)-Bis(2-chloroethyl)diamido)-1,3,2-oxazaphosphoridinoxyd
2,3-N,N(sup 1)-Bis(2-chloroethyl)diamido-1,3,2-oxazaphosphoridinoxyd
2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis( 2-chloroethyl)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide (8CI)
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide
3-(2-Chloroethyl)-2-((2-chloroethyl)amino)perhydro-2H-1,3,2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorineoxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2- oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
3,} 2-oxazaphosphorine oxide
36341-88-5
3778-73-2
84711-20-6
A 4942
AB00513932
AC1L1GHW
AC-2113
Ambap3778-73-2
Asta Z 4942
ASTA Z 4942
BPBio1_000865
BRN 0611835
BSPBio_000785
C07047
CAS-3778-73-2
CCRIS 352
CHEBI:5864
CHEMBL1024
CID3690
Cyfos
D00343
D007069
DB01181
EINECS 223-237-3
HMS1570H07
HMS2090M12
HMS2093N07
Holoxan
Holoxan 1000
HSDB 7023
I06-0494
Ifex
IFEX (TN)
Ifosfamid
Ifosfamida
Ifosfamida [INN-Spanish]
ifosfamide
Ifosfamide (JAN/USP/INN)
|
Ifosfamide [USAN:INN:BAN:JAN]
Ifosfamide Sterile
Ifosfamidum
Ifosfamidum [INN-Latin]
Ifosphamide
Ifsofamide
Iphosphamid
Iphosphamid(e)
Iphosphamide
I-Phosphamide
Iso Endoxan
Isoendoxan
Iso-Endoxan
Isofosfamide
Isophosphamide
isosfamide
Isosfamide
LS-102
LS-99799
Mitoxana
Mitoxana, Ifex, Ifosfamide
MJF 9325
MJF-9325
MLS002154021
MolPort-003-666-704
N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid
N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid [German]
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylen ephosphoric acid diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylene phosphoric acid ester diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid ester diamide
N-(2-Chloroethyl)-N-(3-(2-chloroethyl)-2-oxido-1,3,2-oxazaphosphinan-2-yl)amine
N,3-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
N,N-Bis(beta-chloroethyl)-amino-N',O-propylene-phosphoric acid ester diamide
Naxamide
NCGC00016639-01
NCGC00179435-01
NCI60_000233
NCI-C01638
NPFAPI-04
NSC 109,724
NSC 109724
NSC109,724
NSC-109,724
NSC109724
NSC-109724
Prestwick0_000833
Prestwick1_000833
Prestwick2_000833
Prestwick3_000833
S1302_Selleck
SMR001233348
SPBio_002706
STL058690
UNII-UM20QQM95Y
WLN: T6NPOTJ AM2G BO B2G
Z 4942
Z4942
Z-4942
|
|
4 |
|
Mechlorethamine |
Approved, Investigational |
Phase 3,Phase 2 |
|
51-75-2 |
4033
|
Synonyms:
.Beta.,.beta.'-Dichlorodiethyl-N-methylamine
1, 5-Dichloro-3-methyl-3-azapentane hydrochloride
126-85-2 (N-oxide)
2,2'-Dichlorodiethyl-methylamine
2,2'-Dichloro-N-me
2,2'-dichloro-N-methyldiethylamine
2,2'-Dichloro-N-methyldiethylamine
2-Chloro-N-(2-chloroethyl)-N-methylethanamine
302-70-5 (N-oxide, hydrochloride)
51-75-2
55-86-7 (HYDROCHLORIDE)
AC1L1H9H
Antimit
beta,beta'-Dichlorodiethyl-N-methylamine
beta,Beta'-dichlorodiethyl-N-methylamine
Bis(2-chloroethyl)methylamine
Bis(beta-chloroethyl) methylamine
Bis(beta-chloroethyl)methylamine
BRN 0605323
BSPBio_001947
C07115
C5H11Cl2N
Carolysine
Caryolysin
Caryolysine
CCRIS 447
CHEBI:28925
CHEMBL427
Chloramine (the nitrogen mustard)
Chlorethazine
Chlormethine
Chlormethine (INN)
Chlormethine [INN:BAN]
Chlormethinum [INN-Latin]
CID4033
Cloramin
Clormetina
Clormetina [INN-Spanish]
D07671
DB00888
Di(2-chloroethyl)methylamine
Dichlor amine
Dichloren
DivK1c_000759
EINECS 200-120-5
Embechine
Embichin
ENT-25294
HMS1920J15
HMS2091B04
HMS502F21
HN2
HN-2
HSDB 5083
I14-8708
IBS-L0033631
IDI1_000759
KBio1_000759
KBio2_001369
KBio2_003937
KBio2_006505
|
KBio3_001447
KBioGR_001448
KBioSS_001369
LS-7559
MBA
Me chloroethamine
Mebichloramine
mechlorethamine
Mechlorethamine
Mechlorethanamine
Mechloroethamine
Mecloretamina
Mecloretamina [Italian]
Methylbis(2-chloroethyl)amine
Methylbis(beta-chloroethyl)amine
Methyldi(2-chloroethyl)amine
Mitoxine (*Hydrochloride*)
MolPort-001-785-592
Mustargen
Mustine
Mustine note
Mutagen
N,N-Bis(2-chloroethyl)methylamine
N,N-Bis(2-chloroethyl)-N-methylamine
N,N-Di(chloroethyl)methylamine
NCGC00091835-02
NCGC00091835-03
NCGC00091835-04
NCGC00091835-05
NCI60_041682
NINDS_000759
Nitol (*Hydrochloride*)
Nitrogen mustard
Nitrogen mustard (HN-2)
Nitrogranulogen
N-Lost
N-Methyl lost
N-Methyl-2,2'-dichlorodiethylamine
N-methyl-bis(2-chloroethyl)amine
N-Methyl-bis(2-chloroethyl)amine
N-Methyl-bis(beta-chloroethyl)amine
N-Methyl-bis-chloraethylamin
N-Methyl-bis-chloraethylamin [German]
N-Methyl-lost
N-Methyl-lost [German]
NSC762
SPBio_000496
Spectrum_000889
SPECTRUM1500375
Spectrum2_000448
Spectrum3_000484
Spectrum4_000924
Spectrum5_001702
Stickstofflost (*Hydrochloride*)
Stickstofflost (ebewe)
T 1024
T-1024
thyldiethylamine
TL 146
UNII-50D9XSG0VR
β,β'-dichlorodiethyl-N-methylamine
|
|
5 |
|
Paclitaxel |
Approved, Vet_approved |
Phase 3,Phase 2 |
|
33069-62-4 |
36314
|
Synonyms:
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-epi-Paclitaxel
7-Epipaclitaxel
7-Epi-Paclitaxel
7-epi-Taxol
7-Epitaxol
7-Epi-Taxol
AB00513812
ABI 007
abi-007
ABI007
ABI-007
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
AC1L1IOG
AC1L1VJI
AC1L9AVF
AC-675
ACon1_002231
albumin-bound paclitaxel
Ambotz33069-62-4
ANX-513
Anzatax
Asotax
BIDD:PXR0046
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
Bristaxol
BSPBio_000290
BSPBio_001152
BSPBio_002614
C07394
C466458
C47H51NO14
Capxol
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
cMAP_000068
CPD-8718
D00491
DB01229
DHP-107
DHP-208
DivK1c_000441
DRG-0190
DTS-301
Ebetaxel
EmPAC
Epitaxol
EU-0101201
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
|
KBioGR_000492
KBioGR_001893
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LipoPac
LMPR0104390001
Lopac0_001201
LS-31070
MBT 0206
MEGxp0_001940
Micellar Paclitaxel
Mitotax
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
MPI-5018
nab-paclitaxel
Nanotaxel
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
NCI60_000601
Neuro_000060
NINDS_000441
NK 105
Nova-12005
NP-010981
NSC 125973
NSC125973
NSC-125973
NSC358882
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
paclitaxel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S1150_Selleck
S-8184 Paclitaxel Injectable Emulsion
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
Spectrum_001536
SPECTRUM1503908
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
ST50306996
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TaxAlbin
Taxol
TAXOL (TN)
Taxol A
Taxol Konzentrat
TAXOL, 10-EPI,
Taxol.RTM. (Registered Trademark)
TXL
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
weekly paclitaxel
Xorane
Yewtaxan
|
|
6 |
|
Pancreatic Polypeptide |
Investigational |
Phase 3 |
|
59763-91-6 |
|
7 |
|
Liver Extracts |
|
Phase 3,Phase 2,Phase 1 |
|
|
|
8 |
|
Adjuvants, Anesthesia |
|
Phase 3 |
|
|
|
9 |
|
Analgesics |
|
Phase 3,Phase 2 |
|
|
|
10 |
|
Analgesics, Opioid |
|
Phase 3 |
|
|
|
11 |
|
Anesthetics |
|
Phase 3 |
|
|
|
12 |
|
Anesthetics, General |
|
Phase 3 |
|
|
|
13 |
|
Anesthetics, Intravenous |
|
Phase 3 |
|
|
|
14 |
|
Central Nervous System Depressants |
|
Phase 3,Phase 2 |
|
|
|
15 |
|
Narcotics |
|
Phase 3 |
|
|
|
16 |
|
Peripheral Nervous System Agents |
|
Phase 3,Phase 2 |
|
|
|
17 |
|
Albumin-Bound Paclitaxel |
|
Phase 3,Phase 2 |
|
|
|
18 |
|
Alkylating Agents |
|
Phase 3,Phase 2,Phase 1 |
|
|
|
19 |
|
Antimitotic Agents |
|
Phase 3,Phase 2 |
|
|
|
20 |
|
Antineoplastic Agents, Phytogenic |
|
Phase 3,Phase 2 |
|
|
|
21 |
|
Isophosphamide mustard |
|
Phase 3,Phase 2 |
|
|
0
|
22 |
|
Cola |
Nutraceutical |
Phase 3,Phase 2,Phase 1 |
|
|
|
23 |
|
Indinavir |
Approved |
Phase 2 |
|
150378-17-9 |
5362440
|
Synonyms:
(1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-pentonamide
(1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-Pentonamide
(2S)-1-[(2S,4S)-4-benzyl-2-hydroxy-5-[[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-oxopentyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide
150378-17-9
157810-81-6
157810-81-6 (sulfate (1:1) (salt))
166746-42-5
1c6y
1hsg
1hsh
1k6c
1sdt
1sdu
1sdv
1sgu
216884-06-9
2avo
2avs
2avv
2bpx
AC1L1U7I
AC-20034
AKOS000280989
BIDD:GT0378
BIDD:PXR0141
C07051
C36H47N5O4
|
CHEBI:44032
Compound J
Crixivan
Crixivan (TM)
DB00224
IDV
indinavir
Indinavir (*1:1 Sulfate salt*)
Indinavir [USAN]
Indinavir anhydrous
Indinavir sulfate
Indinavir sulphate
Indinavir, Sulfate (1:1)
L 735524
L-735 524
L-735,524
L-735524
LS-173382
MK-639
MolPort-000-883-804
N-[2(R)-HYDROXY-1(S)-INDANYL]-5-[(2(S)-TERTIARY BUTYLAMINOCARBONYL)-4(3-PYRIDYLMETHYL)PIPERAZINO]-4(S)-HYDROXY-2(R)-PHENYLMETHYLPENTANAMIDE
NCGC00159460-02
NSC697197
Propolis & 4-Hydroxy-N-(2-hydroxy-2,3-dihydro-1H-1-indanyl)-N'-(1,1-dimethylethyl)-2-phenylmethyl-5-[4-(3-pyridylmethyl)-1-piperzinyl]hexanediamide
Propolis+Indinavir
RS-253
UNII-9MG78X43ZT
|
|
24 |
|
Ritonavir |
Approved, Investigational |
Phase 2 |
|
155213-67-5 |
392622
|
Synonyms:
1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
155213-67-5
1hxw
1sh9
538, ABT
5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S)-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
A-84538
Abbott 84538
ABBOTT-84538
ABT 538
ABT 84538
ABT538
ABT-538
AC1L94GB
AC-733
AKOS000280930
BIDD:GT0387
BIDD:PXR0023
Bio-0093
C07240
C37H48N6O5S2
CHEBI:45409
CHEMBL163
CID392622
CPD000466395
D00427
D019438
DB00503
|
DRG-0244
FT-0082824
HMS2051B08
HSDB 7160
LS-148860
MLS000759541
MLS001424063
MolPort-000-883-877
N-[(2S,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl]-N~2~-(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)-L-valinamide
NCGC00159462-02
Norvir
Norvir (TM)
Norvir (TN)
Norvir Sec
NSC693184
RIT
ritonavir
Ritonavir
Ritonavir (JAN/USAN/INN)
Ritonavir [USAN]
Ritonavir is an inhibitor of HIV protease used to treat HIV infection and AIDS.
Ritonavirum
RTV
S1185_Selleck
SAM001246783
SMR000466395
STK634209
ZINC03944422
|
|
25 |
|
Irinotecan |
Approved, Investigational |
Phase 2 |
|
97682-44-5, 100286-90-6 |
60838
|
Synonyms:
(+)-Irinotecan
(4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE
(4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate
1u65
97682-44-5
AC1L1U0Z
AC1Q6PGI
AC-7469
Bio-0054
Biotecan
Biotecan (TN)
BRD-K08547377-003-02-4
BSPBio_002346
C16641
C33H38N4O6
Campothecin-11
Campto
Camptosar
Camptosar, Campto, CPT-11, Irinotecan
Camptothecin-11
CHEBI:105985
CHEMBL481
CID60838
|
CP0
D08086
DB00762
FT-0083650
HSDB 7607
irinotecan
Irinotecan (INN)
Irinotecan [INN:BAN]
Irinotecan Hcl
Irinotecan hydrochloride
Irinotecan Hydrochloride
Irinotecan Hydrochloride Trihydrate
IRINOTECAN HYDROCHLORIDE Trihydrate
IRINOTECAN, CPT-11
Irinotecanum
Irinotecanum [INN-Latin]
LS-44589
NCI60_005051
NSC728073
S1198_Selleck
TL8006026
UNII-7673326042
|
|
26 |
|
Isotretinoin |
Approved |
Phase 2 |
|
4759-48-2 |
5282379
5538
|
Synonyms:
(13-cis)-Retinoate
(13cis)-retinoic acid
(13-cis)-Retinoic acid
(2Z,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid
(2Z,4E6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid
(7e,9e,11e,13Z)-Retinoic acid
(7E,9E,11E,13Z)-retinoic acid
13 cis retinoic acid
13 Cis-Retinoic Acid
13-cis RA
13-cis retinoic acid
13-cis-Retinoate
13-cis-Retinoic acid
13-cis-Vitamin a acid
13-cis-Vitamin A acid
13-RA
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)2-cis-4-trans-6-trans-8-trans-nonatetraenoic acid
4-09-00-02388 (Beilstein Handbook Reference)
4759-48-2
97950-17-9
AC-15388
AC1NQZZ4
Accutane
Accutane (TN)
Ambap302-79-4
Amnesteem
BML2-E07
BPBio1_000080
BRD-K76723084-001-05-9
BRN 1885770
BSPBio_000072
BSPBio_001331
BSPBio_003345
CCRIS 4286
CHEBI:6067
CHEMBL547
CID5282379
CIP-Isotretinoin
cis-RA
cis-Retinoate
cis-Retinoic acid
Claravis
CPD000471891
D00348
D015474
EINECS 225-296-0
EU-0101081
HMS1361C13
HMS1568D14
HMS1791C13
HMS1921D08
HMS1989C13
HMS2092N07
HSDB 3929
IDI1_033801
Isotane
Isotretinoin
|
Isotretinoin (USP)
Isotretinoin [USAN:BAN:INN]
Isotretinoin [USAN:INN:BAN]
Isotretinoin Retinoic acid
Isotretinoin Zinc Salt, 13 cis Isomer
Isotretinoin Zinc Salt, 13-cis-Isomer
Isotretinoina
Isotretinoine
Isotretinoine [INN-French]
isotretinoino
Isotretinoino
Isotretinoino [INN-Spanish]
Isotretinoinum
Isotretinoinum [INN-Latin]
Isotrex
LMPR01090021
Lopac0_001081
LS-143465
MLS001074662
MolPort-003-666-394
NCGC00094358-01
NCGC00094358-02
NCGC00094358-03
NCGC00094358-04
NCGC00094358-05
NCGC00094358-06
NCGC00094358-07
NCGC00094358-08
NCGC00094358-09
NCGC00094358-13
Neovitamin a acid
Neovitamin A acid
Prestwick_642
Prestwick2_000256
Prestwick3_000256
R 3255
R3255_SIGMA
Retinoate
Retinoic acid
Ro 4 3780
Ro 43780
Ro 4-3780
Ro-43780
Ro-4-3780
Roaccutan
Roaccutane
Roacutan
SAM002548955
SMR000471891
Sotret
Sotret (TN)
SPECTRUM1502013
Spectrum5_001795
Spectrum5_001937
Teriosal
UNII-EH28UP18IF
|
|
27 |
|
Aldesleukin |
Approved |
Phase 1, Phase 2 |
|
110942-02-4, 85898-30-2 |
|
Synonyms:
125-L-serine-2-133-interleukin 2 (human reduced)
Interleukin-2 aldesleukin
|
Interleukin-2(2-133),125-ser
Recombinant interleukin-2 human
|
|
28 |
|
Cyclophosphamide |
Approved, Investigational |
Phase 1, Phase 2 |
|
50-18-0, 6055-19-2 |
2907
|
Synonyms:
(-)-Cyclophosphamide
(+-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
Anhydrous cyclophosphamide
ASTA
Asta B 518
ASTA B518
B 518
B-518
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
BRN 0011744
BSPBio_002099
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
CID2907
Clafen
Claphene
CP
CPA
CTX
CY
Cycloblastin
Cyclophosphamid
cyclophosphamide
Cyclophosphamide
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide anhydrous
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
|
D,L-Cyclophosphamide
D07760
DB00531
DivK1c_000246
EINECS 200-015-4
Endoxan
Endoxan R
Endoxana
Endoxanal
Endoxan-Asta
Endoxane
Enduxan
EU-0100238
Genoxal
Hexadrin
HMS2090A12
HSDB 3047
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
Ledoxina
Lopac0_000238
Lopac-C-0768
LS-1302
LS-99787
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI60_002097
NCI-C04900
Neosar
NINDS_000246
NSC 26271
NSC26271
NSC-26271
NSC273033
NSC273034
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra waste number U058
Rcra Waste Number U058
Revimmune
S1217_Selleck
Semdoxan
Sendoxan
Senduxan
SK 20501
SPBio_001071
Spectrum_000858
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
STK177249
STOCK2S-91217
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
|
|
29 |
|
Fludarabine |
Approved |
Phase 1, Phase 2 |
|
21679-14-1, 75607-67-9 |
30751
|
Synonyms:
(2R,3S,4S,5R)-2-(6-amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
(2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
21679-14-1
2-F-ara-A
2-F-ARAA
2-fluoro ARA-A
2-Fluoro Ara-A
2-Fluoro-9-beta-D-arabinofuranosyladenine
9-beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine
9-beta-D-Arabinofuranosyl-2-fluoroadenine
9H-Purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro- (9CI)
AC1LCW8I
AC1Q51CF
C10H12FN5O4
CCRIS 3382
CHEMBL1568
CID657237
CPD000058874
D07966
EINECS 244-525-5
FAMP
FaraA
F-Ara-A
Fludara
Fludara, Fludarabine
Fludarabina
Fludarabina [Spanish]
|
Fludarabine
Fludarabine (INN)
Fludarabine [INN]
Fludarabine 5'-monophosphate
Fludarabine monophosphate
Fludarabine phosphate
Fludarabinum
Fludarabinum [Latin]
Fludura
Fluradosa
Fluradosa (TN)
FT-0082766
HSDB 6964
I14-4978
LS-15061
MLS000028687
NSC 118218
NSC 118218H
NSC-118218
S1491_Selleck
SAM002548956
SMR000058874
SQ Fludarabine
UNII-1X9VK9O1SC
UNII-P2K93U8740
ZINC04216238
|
|
30 |
|
Vidarabine |
Approved, Investigational |
Phase 1, Phase 2 |
|
24356-66-9 |
21704
32326
|
Synonyms:
(+)-Cyclaradine
.beta.-Adenosine
.beta.-D-Adenosine
1odi
2-(6-AMINO-purin-9-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol
2946-52-3
2fqy
2gl0
30143-02-3
3080-29-3
3228-71-5
4005-33-8
46946-45-6
46969-16-8
524-69-6
5536-17-4
58-61-7
9-Arabinosyladenine
9-beta-D-Arabinofuranosyl-9H-purin-6-amine
9-beta-D-arabinofuranosyl-adenine
9-beta-D-Arabinofuranosyladenine
9-beta-D-Arabinofuranosyl-adenine
9-β-D-arabinofuranosyl-9H-purin-6-amine
9-β-D-arabinofuranosyladenine
A 9251
A0152
A4036_SIGMA
A4676_SIGMA
A5762_SIGMA
A9251_SIGMA
AC1L18OL
AC1L1U8O
AC1L2IWM
AC1L2SCM
AC1O4WIN
AC1O8PY7
AC1Q1ID3
AC1Q4Y1Z
AC1Q52XU
Adenine arabinoside
Adenine Arabinoside
Adenine nucleoside
Adenine riboside
Adenine xyloside
adenine-D-ribose
Adenocard
Adenocard (TN)
Adenocard, Adenosine
Adenocor
Adenoscan
Adenoscan (TN)
Adenosin
Adenosin [German]
adenosine
Adenosine (JAN/USP)
Adenosine [USAN:BAN]
Adenosine arabinose
ADENOSINE, U.S.P.
Adenosine-8-14C
Adensoine
Ade-Rib
ADN
AI3-52413
AI3-52821
alpha-Ara A
Ambap5536-17-4
AR-1H6029
Ara A
Ara-A
ARA-A NSC 247519
Araadenosine
Ara-ATP
Arabinoside adenine
Arabinoside Adenine
Arabinosyl adenine
Arabinosyl Adenine
Arabinosyladenine
Arabinosyl-adenine
Arasena-A
Armes
Armes (TN)
BB_NC-0565
beta-Adenosine
beta-Ara A
beta-D-Adenosine
Bio1_000437
Bio1_000926
Bio1_001415
bmse000061
Boniton
BPBio1_000898
BRN 0624881
BSPBio_000816
BSPBio_001796
BSPBio_002000
C00212
CAS-5536-17-4
Caswell No. 010B
CCRIS 2557
CCRIS 3383
CHEBI:136932
CHEBI:16335
CHEBI:45327
CHEMBL1090
CHEMBL20247
CHEMBL477
CI 673
CI-673
CID102198
CID191
CID21704
CID60961
CID6420052
CID6713976
CPD000471872
D000241
D00045
D06298
DB00640
DivK1c_000191
EINECS 200-389-9
EINECS 217-911-6
EINECS 226-893-9
EU-0100123
FT-0082881
HMS1570I18
HMS1920A13
|
HMS1921K05
HMS2090F06
HMS2091G13
HMS2092C16
HMS500J13
HSDB 6514
I01-1121
IDI1_000191
KBio1_000191
KBio2_002418
KBio2_004986
KBio2_007554
KBio3_001296
KBio3_001500
KBioGR_001224
KBioSS_002424
L000094
Lopac0_000123
LS-15059
LS-15085
MEDR-640
MLS000069638
MLS000699527
MLS001066352
MLS001333133
MLS001333134
MLS002153227
MLS002153992
MolPort-001-785-903
MolPort-001-838-229
MolPort-003-666-308
Myocol
NCGC00016656-01
NCGC00023673-03
NCGC00023673-04
NCGC00023673-05
NCGC00023673-06
NCGC00023673-07
NCGC00094579-01
NCGC00094579-02
NCGC00094579-03
NCGC00094579-04
NCGC00178869-01
NCGC00179417-01
nchembio.143-comp9
nchembio.186-comp109
nchembio.64-comp4
nchembio706-5
NCI60_003823
NCI60_037192
NCIOpen2_003303
NCIOpen2_005376
NINDS_000191
NSC 247519
NSC 404241
NSC 627048
NSC 7359
NSC 7652
NSC247519
NSC404241
NSC-404241
NSC627048
NSC70422
NSC7359
NSC7652
NSC80832
NSC87676
NSC91041
Nucleocardyl
Pallacor
PDSP1_001036
PDSP2_001020
Polyadenosine
Polyriboadenosine
Prestwick_983
Prestwick0_000768
Prestwick1_000768
Prestwick2_000768
Prestwick3_000768
RAB
S1647_Selleck
S1784_Selleck
SAM002564191
Sandesin
SMP1_000312
SMR000058216
SMR000225041
SMR000471872
SMR001233326
SPBio_001194
SPBio_001491
SPBio_002755
Spectrum_001894
SPECTRUM1500107
SPECTRUM1500609
Spectrum2_001257
Spectrum2_001336
Spectrum3_000288
Spectrum3_000580
Spectrum4_000782
Spectrum5_001429
Spongoadenosine
SR 96225
SR-96225
STK361815
SUN-Y4001
TL8003749
UNII-3XQD2MEW34
UNII-K72T3FS567
USAF CB-10
V0098
Vidarabin
Vidarabina
Vidarabina [DCIT]
Vidarabine
Vidarabine (JAN)
Vidarabine anhydrous
Vidarabinum
Vira ATM
Vira-A
Vira-A, Vidarabine
VIRDARABINE
XA
Xylosyl A
Xylosyladenine
ZINC00970363
ZINC02169830
|
|
31 |
|
Pembrolizumab |
Approved |
Phase 2 |
|
1374853-91-4 |
|
Synonyms:
|
32 |
|
Daratumumab |
Approved |
Phase 1, Phase 2 |
|
945721-28-8 |
|
Synonyms:
|
33 |
|
nivolumab |
Approved |
Phase 1, Phase 2 |
|
946414-94-4 |
|
Synonyms:
|
34 |
|
Valproic Acid |
Approved, Investigational |
Phase 2 |
|
99-66-1 |
3121
|
Synonyms:
(N-C3H7)2CHCOOH
(S)-2-propyl-4-pentanoate
(S)-2-propyl-4-pentanoic acid
2 PP (base)
2-n-propyl-n-valeric acid
2-n-Propyl-n-valeric acid
2-N-Propyl-N-valeric acid
2-Propylpentanoate
2-Propyl-Pentanoate
2-propyl-pentanoic acid
2-Propylpentanoic acid
2-Propylpentanoic Acid
2-Propyl-Pentanoic acid
2-propylvaleric acid
2-Propylvaleric acid
2-Propylvaleric Acid
4-heptanecarboxylic acid
4-Heptanecarboxylic acid
76584-70-8 (hydrochloride salt (2:1))
99-66-1
Abbott 44090
AC1L1F7T
AC1Q2ULA
Acide valproique
acide valproïque
Acide valproique [inn-french]
Acide valproique [INN-French]
Acido valproico
ácido valproico
Acido valproico [inn-spanish]
Acido valproico [INN-Spanish]
acidum valproicum
Acidum valproicum
Acidum valproicum [inn-latin]
Acidum valproicum [INN-Latin]
AI3-10500
Alti-valproic
Alti-Valproic
APO-divalproex
Apo-valproic
Apo-valproic syrup
Avugane
Baceca
BIDD:GT0858
BRN 1750447
C07185
CHEBI:39867
CHEMBL109
CID3121
Convulex
Convulsofin
CPD000499581
D00399
DB00313
Delepsine
Depacon
Depakene
Depakene (TN)
Depakin
Depakin chrono
Depakine
Depakine chrono
Depakote
Depakote (TM)
Deproic
di-n-propylacetic acid
Di-n-propylacetic acid
Di-N-propylacetic acid
Di-n-propylessigsaeure
Di-n-propylessigsaure
Di-N-propylessigsaure
Di-n-propylessigsäure
Di-n-propylessigsaure [German]
Di-N-propylessigsaure [german]
Dipropyl Acetate
Dipropylacetate
Dipropylacetic acid
Divalproex
DivK1c_000273
DOM-divalproex
Dom-valproate
Dom-Valproic
DOM-valproic
Dom-valproic acid
DOM-valproic acid E.C.
Dom-valproic acid syrup
DPA
EINECS 202-777-3
Epiject I.V.
Epilex
Epilim
Epival
Epival er
Ergenyl
G2M-777
Gen-divalproex
HMS2089J06
HSDB 3582
I04-0211
InChI=1/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)
KBio1_000273
KBio2_001001
|
KBio2_002277
KBio2_003569
KBio2_004845
KBio2_006137
KBio2_007413
KBio3_002626
KBio3_002757
KBioGR_000871
KBioGR_002277
KBioSS_001001
KBioSS_002278
Kyselina 2-propylvalerova
Kyselina 2-propylvalerova [Czech]
LS-161170
LS-2068
Med valproic
Med Valproic
MLS001076682
MLS001335927
MLS001335928
MLS002415770
MolPort-001-791-895
Mylproin
Myproate
Myproic acid
Myproic Acid
NCGC00091149-01
NCGC00091149-02
NCGC00091149-03
NCGC00091149-04
nchembio.79-comp4
nchembio815-comp21
n-Dipropylacetic acid
N-Dipropylacetic acid
n-DPA
N-DPA
NINDS_000273
Novo-divalproex
Novo-valproic
Novo-Valproic
Novo-Valproic - ECC
Novo-valproic soft gel cap
NSC 93819
NSC93819
Nu-valproic
Nu-Valproic
P0823
P6273_SIGMA
PEAC
Penta-valproic
Penta-Valproic
PHL-valproate
PHL-valproic acid
PHL-valproic acid E.C.
PMS-Divalproex
PMS-valproate
PMS-valproic acid
PMS-Valproic Acid
PMS-valproic acid E.C.
Propylvaleric acid
Ratio-Valproic - ECC
S(-)-4-En-valproate
S(-)-4-En-valproic acid
S-2-N-Propyl-4-pentenoate
S-2-N-Propyl-4-pentenoic acid
SAM002564230
Sandoz valproic
Savicol
SBB065764
Semisodium Valproate
SMR000499581
Sodium hydrogen divalproate
SPBio_000912
Spectrum_000521
Spectrum2_000946
Spectrum3_001733
Spectrum4_000376
Sprinkle
Stavzor
UNII-614OI1Z5WI
Valcote
Valparin
valproate
Valproate
Valproate semisodique [French]
Valproate semisodium
Valproato semisodico [Spanish]
Valproatum seminatricum [Latin]
valproic acid
Valproic acid
VALPROIC ACID
Valproic acid (USP)
Valproic acid [usan:ban:inn]
Valproic acid [USAN:INN:BAN]
Valproic acid USP
Valproic acid USP24
Valproic Acid, Sodium Salt (2:1)
Valproinsaeure
Valproinsäure
VPA
Vupral
WLN: QVY3 & 3
|
|
35 |
|
Vinblastine |
Approved |
Phase 2 |
|
865-21-4 |
241903
13342
|
Synonyms:
(2ALPHA,2'BETA,3BETA,4ALPHA,5BETA)-VINCALEUKOBLASTINE
(2xi,3beta,4'beta,19xi)-vincaleukoblastine
(3aR-(3aalpha,4beta,5beta,5abeta,9(3R*,5S*,7R*,9S*),10bR*,13aalpha))-methyl 4-(acetyloxy)-3a-ethyl-9-(5-ethyl-1,4,5,6,7,8,9,10-octahydro-5-hydroxy-9-(methoxycarbonyl)-2H-3,7-methanoazacycloundecino(5,4-b)indol-9-yl)-3a,4,5,5a,6,11,12,13a-octahydro-5-hydroxy-8-methoxy-6-methyl-1H-indolizino(8,1-cd)carbazole-5-carboxylate
143-67-9
1z2b
29060-LE
865-21-4
AC1L21JC
AC1L68D2
AC1MXZJ2
AC-20335
BIDD:PXR0201
Bio-0111
BRD-K01188359-065-02-5
BSPBio_001228
BSPBio_003594
C07201
C46H58N4O9
CCRIS 9002
CHEBI:171516
CHEBI:27375
CHEMBL159
CHEMBL607706
CID13342
CID241903
CID3823887
CID6710780
D08675
DB00570
EINECS 212-734-0
HMS2090K05
HSDB 3263
KBio3_003033
LS-1859
LS-187263
MolPort-002-518-262
MolPort-005-910-359
|
NCGC00022585-04
NCGC00181127-01
NChemBio.2007.10-comp22
nchembio873-comp22
NCI60_004200
NCI-C04842
NDC 0002-1452-01
Neuro_000020
Nincaluicolflastine
NSC 47842
Rozevin
SPBio_000680
Spectrum2_000890
Spectrum3_001994
STOCK1N-38480
UNII-5V9KLZ54CY
Velban
Velbe
Vinblastin
Vinblastina
Vinblastina (TN)
Vinblastina [Dcit]
Vinblastina [DCIT]
vinblastine
Vinblastine
Vinblastine (INN)
Vinblastine [INN:BAN]
Vinblastine Sulfate
Vinblastinum
Vinblastinum [INN-Latin]
Vincaleucoblastin
Vincaleucoblastine
Vincaleukoblastine
Vincoblastine
VLB
VR-8
|
|
36 |
|
Tretinoin |
Approved, Investigational, Nutraceutical |
Phase 2 |
|
302-79-4 |
5538
|
Synonyms:
(all-e)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid
.beta.-Retinoic acid
[3H]Retinoic acid
13497-05-7 (hydrochloride salt)
15-Apo-beta-caroten-15-oic acid
187175-63-9
1n4h
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoic acid (ecl)
302-79-4
5300-03-8
56573-65-0
7005-78-9
9(Z)-Retinoic acid
9-cis-RA
A-Acido (Argentina)
Aberel
Aberela
Aberela [Norway]
AC1L9GWO
AC1Q1J2J
AC-6824
Accutane Roche
Acid A Vit (Belgium, Netherlands)
Acid, all-trans-Retinoic
Acid, beta-all-trans-Retinoic
Acid, Retinoic
Acid, trans-Retinoic
Acid, Vitamin A
Acide retinoique (french) (dsl)
Acide retinoique (French) (DSL)
Acnavit
Acnavit [Denmark]
AGN 100335
AGN 192013
Airol
Aknefug
Aknoten
AKOS000280845
Alitretinoin
All Trans Retinoic Acid
all trans-Retinoic acid
All Trans-Retinoic Acid
all-(e)-Retinoic acid
all-(E)-Retinoic acid
All-trans Retinoic Acid
all-trans-beta-Retinoic acid
all-trans-b-Retinoic acid
all-trans-Retinoic acid
Alltrans-retinoic acid
all-trans-Tretinoin
all-trans-Vitamin a acid
all-trans-Vitamin A acid
all-trans-Vitamin a1 acid
all-trans-Vitamin A1 acid
ALRT 1057
Amnesteem
ATRA
AT-RA
Atragen
Atra-IV
Atralin
Avita (TN)
Avita Gel
A-Vitaminsyre
A-Vitaminsyre [Denmark]
Avitoin
Avitoin [Norway]
BAL4079
beta all trans Retinoic Acid
beta-all-trans-Retinoic acid
beta-Ra
beta-Retinoic acid
beta-Retinoic Acid
Betarretin
BIDD:GT0483
BIDD:PXR0081
BML2-E05
bmse000562
BPBio1_000082
b-Retinoic acid
BRN 2057223
BSPBio_000074
BSPBio_001500
C00777
CCRIS 3294
CCRIS 7098
CHEBI:15367
CHEMBL38
CID444795
Claravis
Cordes vas
Cordes VAS [Germany]
CPD000058245
D00094
D014212
DB00523
DB00755
DB00982
Dermairol
Effederm
Effederm [France]
EINECS 206-129-0
Epi-aberel
EU-0101061
Eudyna
HMS1361K22
HMS1568D16
HMS1791K22
HMS1921D14
HMS1989K22
HMS2089D20
HMS2092N11
HMS502N05
HSDB 2169
HSDB 7186
|
I04-0008
I14-2351
IDI1_000903
IDI1_033970
Isotretinoin Retinoic acid
L000833
LGD 100057
LMPR01090019
Lopac0_001061
LS-1154
Lsotretinoin
MLS000028588
MLS001076515
MLS002207234
MLS002222211
MolPort-000-883-857
NCGC00017280-06
NCGC00017280-17
NCGC00021808-04
NCGC00021808-05
NCGC00021808-06
NCGC00021808-07
NCGC00021808-09
NCGC00021808-14
NCGC00021808-15
nchembio.154-comp2
Nexret
NSC 122758
NSC122758
NSC-122758
Panretin Gel
Panretyn
PDT-002-002
Potassium Salt, Tretinoin
Prestwick_424
Prestwick2_000257
Prestwick3_000257
R 2625
R0064
R2625_SIGMA
REA
Renova
Renova (TN)
Retacnyl
Retin A
Retin A (TN)
Retin-A
Retin-A Micro
Retinoate
Retinoic acid
RETINOIC acid
RETINOIC ACID, ALL TRANS
Retinoic acid, all-trans- (8CI)
Retinova
Retionic acid
Retionic Acid
Retisol-A
Ro 1-5488
S1653_Selleck
Salt, Tretinoin Potassium
Salt, Tretinoin Sodium
Salt, Tretinoin Zinc
SAM002264647
SMR000058245
Sodium Salt, Tretinoin
Solage
Sotret
SPECTRUM1502016
Spectrum5_001746
Spectrum5_001933
SR-01000000239
SR-01000000239-14
ST057075
Stieva-a
Stieva-A
Stieva-a Forte
trans Retinoic Acid
trans-Retinoic acid
Tretin m
Tretin M
tretinoin
Tretinoin
Tretinoin (JAN/USP/INN)
Tretinoin (TN)
Tretinoin [USAN:INN:BAN]
Tretinoin 0.1% cream or placebo
tretinoin liposome
Tretinoin Potassium Salt
Tretinoin Sodium Salt
Tretinoin Zinc Salt
Tretinoin/All-Trans Retinoic Acid
Tretinoina
Tretinoina [INN-Spanish]
Tretinoine
Trétinoïne
tretinoine (French) (EINECS)
Tretinoine (french) (einecs)
Tretinoine [INN-French]
Tretinoino
Tretinoino [INN-Spanish]
Tretinoinum
Tretinoinum [INN-Latin]
TRETINON
Tri-Luma
UNII-1UA8E65KDZ
UNII-5688UTC01R
UPCMLD-DP097
Vesanoid
Vesanoid (TN)
Vesanoid, Airol, Renova, Atralin, Retin-A, Avita, Tretinoin
Vesnaroid
Vitamin A acid
Vitinoin
WLN: L6UTJ A1 B1U1Y1 & U2U1Y1 & U1VQ C1 C1
WLN: L6UTJ A1 B1U1Y1&U2U1Y1&U1VQ C1 C1
Zinc Salt, Tretinoin
|
|
37 |
|
Camptothecin |
Experimental |
Phase 2 |
|
7689-03-4 |
|
Synonyms:
(+)-camptothecin
(+)-camptothecine
(s)-(+)-camptothecin
(s)-camptothecin
|
20(S)-Camptothecin
21,22-Secocamptothecin-21-oic acid lactone
Camptothecine
D-camptothecin
|
|
38 |
|
Docetaxel |
Approved May 1996, Investigational |
Phase 2 |
|
114977-28-5 |
148124
9877265
|
Synonyms:
(2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-[[(1,1-dimethylethoxy)carbonyl]amino]-a-hydroxybenzenepropanoate
01885_FLUKA
114977-28-5
4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
4-(Acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
AC1L3WHJ
AC-383
ANX-514
BIND-014
C11231
CHEBI:4672
CHEMBL92
CID148124
D07866
DB01248
docetaxel
Docetaxel
Docetaxel (INN)
docetaxel 114977-28-5
Docetaxel anhydrous
Docetaxel, Trihydrate
|
EmDOC
HMS2089K08
InChI=1/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,5
MolPort-003-847-005
nchembio.188-comp8
nchembio.2007.34-comp7
nchembio.573-comp11
nchembio853-comp8
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-Boc-10-deacetyl taxol
NSC-628503
PSMA-targeted docetaxel nanoparticle
RP-56976
SDP-014
Taxotere
Taxotere (TN)
Taxotere(R)
TXL
XRP-6976L
|
|
39 |
|
Anti-HIV Agents |
|
Phase 2,Phase 1 |
|
|
|
40 |
|
Anti-Infective Agents |
|
Phase 2,Phase 1 |
|
|
|
41 |
|
Anti-Retroviral Agents |
|
Phase 2,Phase 1 |
|
|
|
42 |
|
Antiviral Agents |
|
Phase 2,Phase 1 |
|
|
|
43 |
|
Cytochrome P-450 CYP3A Inhibitors |
|
Phase 2 |
|
|
|
44 |
|
Cytochrome P-450 Enzyme Inhibitors |
|
Phase 2 |
|
|
|
45 |
|
HIV Protease Inhibitors |
|
Phase 2 |
|
|
|
46 |
|
protease inhibitors |
|
Phase 2 |
|
|
|
Synonyms:
|
47 |
|
interferons |
|
Phase 2,Phase 1 |
|
|
|
48 |
|
topoisomerase I inhibitors |
|
Phase 2 |
|
|
|
49 |
|
Topoisomerase Inhibitors |
|
Phase 2 |
|
|
|
50 |
|
Vaccines |
|
Phase 2,Phase 1 |
|
|
|
Interventional clinical trials:
(show all 47)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain |
Completed |
NCT00538850
|
Phase 3 |
Fentanyl sublingual spray;Placebo |
2 |
International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study) |
Not yet recruiting |
NCT02305654
|
Phase 3 |
Paclitaxel;Ifosfamide;Cisplatin |
3 |
External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases |
Unknown status |
NCT00637637
|
Phase 2 |
indinavir sulfate;ritonavir |
4 |
Irinotecan and Cisplatin in Treating Patients With Locally Advanced or Metastatic Penile Cancer |
Completed |
NCT00066391
|
Phase 2 |
cisplatin;irinotecan hydrochloride |
5 |
Neoadjuvant Chemotherapy for Patients With Squamous Cell Carcinoma of the Penis |
Completed |
NCT00512096
|
Phase 2 |
Ifosfamide;Paclitaxel (Taxol);Cisplatin |
6 |
A Trial of Cabazitaxel Chemotherapy in Relapsed Locally Advanced &/or Metastatic Carcinoma of the Penis |
Completed |
NCT03114254
|
Phase 2 |
Cabazitaxel |
7 |
Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males |
Completed |
NCT01209325
|
Phase 2 |
|
8 |
Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer |
Completed |
NCT00002506
|
Phase 2 |
isotretinoin |
9 |
T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers |
Completed |
NCT02280811
|
Phase 1, Phase 2 |
Fludarabine;Cyclophosphamide;Aldesleukin |
10 |
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers |
Completed |
NCT01585428
|
Phase 2 |
Fludarabine;Cyclophosphamide;Aldesleukin |
11 |
Evaluation of Lymphadenectomy and Chemotherapy TIP on Inguinal Lymph Nodes in Squamous Cell Carcinoma of the Penis (AFU-GETUG 25) |
Recruiting |
NCT02817958
|
Phase 2 |
Chemotherapie TIP |
12 |
Dacomitinib (PF-00299804) in Advanced/Metastatic Squamous Cell Carcinoma of the Penis |
Recruiting |
NCT01728233
|
Phase 2 |
Dacomitinib |
13 |
Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma |
Recruiting |
NCT02837042
|
Phase 2 |
Pembrolizumab |
14 |
An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors |
Recruiting |
NCT02488759
|
Phase 1, Phase 2 |
Nivolumab;Ipilimumab;BMS-986016;Daratumumab |
15 |
HPV Anti-CD40 RNA Vaccine |
Recruiting |
NCT03418480
|
Phase 1, Phase 2 |
HPV vaccine |
16 |
M7824 in Subjects With HPV Associated Malignancies |
Recruiting |
NCT03427411
|
Phase 2 |
M7824 |
17 |
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors |
Recruiting |
NCT03333616
|
Phase 2 |
Ipilimumab;Nivolumab |
18 |
Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors |
Recruiting |
NCT02721732
|
Phase 2 |
Pembrolizumab |
19 |
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors |
Recruiting |
NCT02834013
|
Phase 2 |
|
20 |
Avelumab With Valproic Acid in Virus-associated Cancer |
Recruiting |
NCT03357757
|
Phase 2 |
Valproic Acid |
21 |
A Phase II Trial of Vinflunine Chemotherapy in Locally-advanced and Metastatic Carcinoma of the Penis (VinCaP) |
Active, not recruiting |
NCT02057913
|
Phase 2 |
Vinflunine |
22 |
A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy |
Not yet recruiting |
NCT03391479
|
Phase 2 |
Avelumab |
23 |
S0224, Docetaxel in Treating Patients With Locally Advanced or Metastatic Penile Cancer (TERMINATED) |
Terminated |
NCT00058448
|
Phase 2 |
docetaxel |
24 |
Study With Pazopanib and Weekly Paclitaxel in Penile Carcinoma (PAZOPEN-SOGUG) |
Terminated |
NCT02279576
|
Phase 2 |
Pazopanib;Paclitaxel |
25 |
Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE) |
Withdrawn |
NCT02014831
|
Phase 2 |
Cetuximab;TIP |
26 |
Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions |
Unknown status |
NCT00066404
|
Phase 1 |
|
27 |
Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer |
Completed |
NCT00019110
|
Phase 1 |
|
28 |
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma |
Completed |
NCT00020579
|
Phase 1 |
entinostat |
29 |
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma |
Completed |
NCT00083213
|
Phase 1 |
|
30 |
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma |
Completed |
NCT00082823
|
Phase 1 |
|
31 |
Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer |
Completed |
NCT00003704
|
Phase 1 |
capecitabine |
32 |
Cisplatin-based Chemotherapy Combined With P16_37-63 Peptide Vaccination in Patients With HPV-positive Cancers |
Completed |
NCT02526316
|
Phase 1 |
|
33 |
Cabozantinib-s-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors |
Recruiting |
NCT02496208
|
Phase 1 |
Cabozantinib S-malate |
34 |
HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA |
Recruiting |
NCT02379520
|
Phase 1 |
Cytoxan;Fludarabine |
35 |
Characterising Metastatic Penile Cancer Using Molecular Imaging - Hybrid MRI-PET [MRI-PET] |
Unknown status |
NCT02104063
|
|
|
36 |
Videoscopic Versus Open Inguinal Lymphadenectomy for Cancer |
Completed |
NCT01526486
|
|
|
37 |
Interactive, Health Literacy Promoting Text Messages and HPV Vaccine Completion In Minority Adolescents |
Completed |
NCT02236273
|
|
|
38 |
Cancer in Patients With Gabapentin (GPRD) |
Completed |
NCT01236053
|
|
Gabapentin prescriptions |
39 |
OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer |
Completed |
NCT00900302
|
|
|
40 |
Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients |
Completed |
NCT00253383
|
|
|
41 |
HOUSTON - HPV-related Oropharyngeal and Uncommon Cancers Screening Trial Of Men |
Recruiting |
NCT02897427
|
|
|
42 |
Laser Fluorescence in Cancer Surgical Treatment |
Recruiting |
NCT03021200
|
|
|
43 |
Development of Diagnostics and Treatment of Urological Cancers |
Recruiting |
NCT02994758
|
|
|
44 |
Integrated Cancer Repository for Cancer Research |
Recruiting |
NCT02012699
|
|
|
45 |
Pharmacological Penile Rehabilitation in the Preservation of Erectile Function Following Bilateral Nerve-Sparing Radical Prostatectomy |
Active, not recruiting |
NCT00955929
|
|
Placebo QHS and sildenafil and questionnaires;Sildenafil and questionnaire;Trimix combination (Papavarine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mmL) and questionnaires |
46 |
Engaging Patients and Providers in Collaborative Communication on HPV Vaccination (EPICC-HPV) |
Not yet recruiting |
NCT03267251
|
|
|
47 |
Integrating a Health Information Technology System for Primary and Secondary Cervical Cancer Prevention |
Not yet recruiting |
NCT03346915
|
|
|
Cochrane evidence based reviews: penile neoplasms
|